IGF-1R
シグナル伝達経路
研究分野
阻害剤の選択性比較
| カタログ番号 | 製品カタログ | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | アルコール | ||
| S1091 | Linsitinib (OSI-906) | <1 mg/mL | 84 mg/mL | <1 mg/mL |
| S1034 | NVP-AEW541 | <1 mg/mL | 88 mg/mL | <1 mg/mL |
| S1093 | GSK1904529A | <1 mg/mL | 124 mg/mL | <1 mg/mL |
| S1088 | NVP-ADW742 | <1 mg/mL | 10 mg/mL | 3 mg/mL |
| S1012 | BMS-536924 | <1 mg/mL | 96 mg/mL | <1 mg/mL |
| S2703 | GSK1838705A | <1 mg/mL | 107 mg/mL | <1 mg/mL |
| S1124 | BMS-754807 | <1 mg/mL | 92 mg/mL | 92 mg/mL |
| S8003 | PQ 401 | <1 mg/mL | 32 mg/mL | <1 mg/mL |
| S7106 | AZD3463 | <1 mg/mL | 24 mg/mL | <1 mg/mL |
| S8228 | NT157 | <1 mg/mL | 82 mg/mL | 82 mg/mL |
| S7668 | Picropodophyllin (PPP) | <1 mg/mL | 82 mg/mL | 1 mg/mL |
亜型選択性的な製品
IGF-1R製品
| 製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
|---|---|---|---|
| S1091 |
Linsitinib (OSI-906)Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3. |
|
|
| S1034 |
NVP-AEW541NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay. |
Inhibition of IGF-IR/InsR or PI3K abrogates AKT membrane localization and phosphorylation. MCF-7/LTED cells were transfected with an AKT PH-GFP plasmid. On day four, cells were treated with 100 ng/ml IGF-I in serum-free medium for 15 minutes, or pre-incubated with 10% DCC-FBS ?1 uM AEW541 or 1 uM BKM120 for 30 minutes followed by treatment with 2 uM AZD5363 for four hours. Cells were viewed in a LSM 510Meta confocal microscope at 40x magnification.
|
|
| S1093 |
GSK1904529AGSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc. |
Inhibition of IGF-1 induced IGF-1R phosphorylation by GSK1904529A. A549 cells were serum-starved O/N and pre-incubated for 4 h with 5 μM GSK1904529A, followed by stimulation with 50ng/ml IGF-1. + IGF-1: positive control; -S: negative control. |
|
| S1088 |
NVP-ADW742NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit. |
HER3 plus IGF-1R up-regulation contribute to enhanced SKOV3/T cell proliferation. (A) SKOV3/T cells transfected with HER3 or control shRNA were treated with 2 μM NVP-ADW742 (NVP) followed by SRB assay. Values are mean ± SD from 3 independent experiments. **P < 0.01, NVP-ADW742 treated group or HER3 shRNA group vs. control. (B) SKOV3/T cells transfected with HER3 or control shRNA were treated with or without 2 μM NVP-ADW742 (NVP) and their cell cycle distribution determined by flow cytometry. The data are representative of 3 independent experiments. |
|
| S1012 |
BMS-536924BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2. |
A, cell viability reduction. TC1889 cells were treated with pharmacological inhibitors against IGF-1R (NVP and BMS), as well as a neutralizing IGF-1R antibody (aIR3) and cell viability was assessed using MTT-assays. Mouse IgG1 antibody was employed as a reference control for the effects of aIR3 at respective concentrations. Assays were performed in sextuple. Data are expressed as the mean SD (n 3). B, induction of cell death. TC1889 cells were treated with pharmacological inhibitors against IGF-1R as well as a neutralizing IGF-1R antibody and cell death was evaluated by FACS-analyses following PI-staining. Data are expressed as the mean SD (n =3). |
|
| S2703 |
GSK1838705AGSK1838705A is a potent IGF-1R inhibitor with IC50 of 2.0 nM, modestly potent to IR and ALK with IC50 of 1.6 nM and 0.5 nM, respectively, and little activity to other protein kinases. |
GSK1838705A suppresses glioma tumor growth and induces apoptosis in vivo. (A) Following inoculation of U87MG cells, formulated vehicle control or GSK1838705A (4 and 8 mg/kg) was injected into the corresponding group of nude mice (n=6/group) once daily. The tumors were measured every other day for 11 days and the tumor volumes were calculated. Starting on day 7, the differences between the treatment groups (4 and 8 mg/kg) and the vehicle control group were significant (P<0.05). (B) Body weights of the mice during the course of treatment were measured as an indication of significant cytotoxic effects. The data are expressed as the mean ± standard deviation. No significant differences are observed between any two of the groups during the course of treatment. (C) At the end of treatment, the tumors were harvested. GSK1838705A (8 mg/kg) induced the apoptosis of tumor cells in vivo, determined using a TUNEL assay (green) and nuclear staining with Hoechst (blue). Representative images are shown (magnification, ×40). TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling. |
|
| S1124 |
BMS-754807BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2. |
|
|
| S8003 |
PQ 401PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM. |
IGF-1R is key determinant of the EI24-mediated gefitinib sensitivity. (A and B) EI24-knockdown cells were treated with the indicated concentrations of inhibitorsfor 24 h before cell viability was measured by the MTT assay. Error bars, S.D., p-values were calculated using unpaired t-test.*p < 0.01,**p = 0.0003,***p < 0.0001. (C and D)EI24-knockdown cells were fixed and stained with crystal violet after 14 days treatment with concentrations of gefitinib (0.1 M), PQ401 (5 M), and AG1024 (20 M). (Eand F) Kaplan–Meier survival plots were obtained using Kaplan–Meier Plotter and display the probability of overall survival of lung cancer patients grouped according toEI24 (208289 s at, E) and IGF-1R (203627 at, F) expression. p-Values were calculated using the log-rank test.
|
|
| S7106 |
AZD3463AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency. |
(E) Immunoblot analysis of lysates of A4573 and TC32 cells following exposure to media only (Control, C); ST/V and V/ST with (+) or without (-) 20 nM AZD3463 using antibodies against ALK, IGF-1R, STAT3 (Y705), p-STAT3, AKT, p-AKT (S473), MAPK, p-MAPK (p42/44). |
|
| S8228 |
NT157NT157, a selective inhibitor of IRS-1/2(insulin receptor substrate), has the potential to inhibit IGF-1R and STAT3 signaling pathways in cancer cells and stroma cells of TME leading to a decrease in cancer cell survival. |
||
| S7668 |
Picropodophyllin (PPP)Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R). |
CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1 µM PPP and were immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n = 4).
|
| 製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
|---|---|---|---|
| S1091 |
Linsitinib (OSI-906)Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3. |
|
|
| S1034 |
NVP-AEW541NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay. |
Inhibition of IGF-IR/InsR or PI3K abrogates AKT membrane localization and phosphorylation. MCF-7/LTED cells were transfected with an AKT PH-GFP plasmid. On day four, cells were treated with 100 ng/ml IGF-I in serum-free medium for 15 minutes, or pre-incubated with 10% DCC-FBS ?1 uM AEW541 or 1 uM BKM120 for 30 minutes followed by treatment with 2 uM AZD5363 for four hours. Cells were viewed in a LSM 510Meta confocal microscope at 40x magnification.
|
|
| S1093 |
GSK1904529AGSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc. |
Inhibition of IGF-1 induced IGF-1R phosphorylation by GSK1904529A. A549 cells were serum-starved O/N and pre-incubated for 4 h with 5 μM GSK1904529A, followed by stimulation with 50ng/ml IGF-1. + IGF-1: positive control; -S: negative control. |
|
| S1088 |
NVP-ADW742NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit. |
HER3 plus IGF-1R up-regulation contribute to enhanced SKOV3/T cell proliferation. (A) SKOV3/T cells transfected with HER3 or control shRNA were treated with 2 μM NVP-ADW742 (NVP) followed by SRB assay. Values are mean ± SD from 3 independent experiments. **P < 0.01, NVP-ADW742 treated group or HER3 shRNA group vs. control. (B) SKOV3/T cells transfected with HER3 or control shRNA were treated with or without 2 μM NVP-ADW742 (NVP) and their cell cycle distribution determined by flow cytometry. The data are representative of 3 independent experiments. |
|
| S1012 |
BMS-536924BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2. |
A, cell viability reduction. TC1889 cells were treated with pharmacological inhibitors against IGF-1R (NVP and BMS), as well as a neutralizing IGF-1R antibody (aIR3) and cell viability was assessed using MTT-assays. Mouse IgG1 antibody was employed as a reference control for the effects of aIR3 at respective concentrations. Assays were performed in sextuple. Data are expressed as the mean SD (n 3). B, induction of cell death. TC1889 cells were treated with pharmacological inhibitors against IGF-1R as well as a neutralizing IGF-1R antibody and cell death was evaluated by FACS-analyses following PI-staining. Data are expressed as the mean SD (n =3). |
|
| S2703 |
GSK1838705AGSK1838705A is a potent IGF-1R inhibitor with IC50 of 2.0 nM, modestly potent to IR and ALK with IC50 of 1.6 nM and 0.5 nM, respectively, and little activity to other protein kinases. |
GSK1838705A suppresses glioma tumor growth and induces apoptosis in vivo. (A) Following inoculation of U87MG cells, formulated vehicle control or GSK1838705A (4 and 8 mg/kg) was injected into the corresponding group of nude mice (n=6/group) once daily. The tumors were measured every other day for 11 days and the tumor volumes were calculated. Starting on day 7, the differences between the treatment groups (4 and 8 mg/kg) and the vehicle control group were significant (P<0.05). (B) Body weights of the mice during the course of treatment were measured as an indication of significant cytotoxic effects. The data are expressed as the mean ± standard deviation. No significant differences are observed between any two of the groups during the course of treatment. (C) At the end of treatment, the tumors were harvested. GSK1838705A (8 mg/kg) induced the apoptosis of tumor cells in vivo, determined using a TUNEL assay (green) and nuclear staining with Hoechst (blue). Representative images are shown (magnification, ×40). TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling. |
|
| S1124 |
BMS-754807BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2. |
|
|
| S8003 |
PQ 401PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM. |
IGF-1R is key determinant of the EI24-mediated gefitinib sensitivity. (A and B) EI24-knockdown cells were treated with the indicated concentrations of inhibitorsfor 24 h before cell viability was measured by the MTT assay. Error bars, S.D., p-values were calculated using unpaired t-test.*p < 0.01,**p = 0.0003,***p < 0.0001. (C and D)EI24-knockdown cells were fixed and stained with crystal violet after 14 days treatment with concentrations of gefitinib (0.1 M), PQ401 (5 M), and AG1024 (20 M). (Eand F) Kaplan–Meier survival plots were obtained using Kaplan–Meier Plotter and display the probability of overall survival of lung cancer patients grouped according toEI24 (208289 s at, E) and IGF-1R (203627 at, F) expression. p-Values were calculated using the log-rank test.
|
|
| S7106 |
AZD3463AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency. |
(E) Immunoblot analysis of lysates of A4573 and TC32 cells following exposure to media only (Control, C); ST/V and V/ST with (+) or without (-) 20 nM AZD3463 using antibodies against ALK, IGF-1R, STAT3 (Y705), p-STAT3, AKT, p-AKT (S473), MAPK, p-MAPK (p42/44). |
|
| S8228 |
NT157NT157, a selective inhibitor of IRS-1/2(insulin receptor substrate), has the potential to inhibit IGF-1R and STAT3 signaling pathways in cancer cells and stroma cells of TME leading to a decrease in cancer cell survival. |
||
| S7668 |
Picropodophyllin (PPP)Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R). |
CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1 µM PPP and were immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n = 4).
|
